GreenRoc Accelerates their World Class Project to Production as Early as 2028. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFaron Pharmaceuticals Share News (FARN)

Share Price Information for Faron Pharmaceuticals (FARN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 104.00
Bid: 100.00
Ask: 108.00
Change: -1.00 (-0.95%)
Spread: 8.00 (8.00%)
Open: 106.50
High: 105.00
Low: 101.50
Prev. Close: 105.00
FARN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Quiz sales fall, names new CEO; Byotrol eyes AIM exit

Wed, 03rd Apr 2024 10:59

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

----------

Quiz PLC - Glasgow, Scotland-based fashion retailer - Chief Executive Officer Tarak Ramzan, who also founded Quiz and is largest shareholder, steps down from post. He takes on a non-executive director role. Chief Commercial Officer Sheraz Ramzan takes over as CEO immediately. "He will implement a turnaround strategy to recalibrate the Quiz brand, its product offering, and reconnect with consumers with the aim of moving the business back into profitable growth," the firm says. Non-Executive Chair Peter Cowgill to take a "more active role in supporting the Company through to conclusion of the ongoing review of strategic options". Cowgill was formerly executive chair of JD Sports Fashion PLC. Quiz adds: "In addition to these changes, the board continues to search for at least one additional independent non-executive director following Charlotte O'Sullivan's departure in November 2023 and will provide an update in due course." Quiz says UK sales continue to be "impacted by subdued levels of traffic both in-store and online". Between the start of 2024 up to February 29, sales fell 9% on-year to GBP8.6 million. Sales since the start of the financial year on April 1 until the end of February fell 12% annually to GBP74.4 million. Expects revenue and a pretax loss in line with expectations. Quiz adds: "The group is taking a number of positive steps to counter the impact of the declining revenues including targeting cost savings for the forthcoming year, eliminating loss making activities, reviewing operational efficiencies and optimising its product offer."

----------

Byotrol PLC - manufacturer of biocidal and antimicrobial cleaning products - Proposes cancellation of AIM listing and re-registration as private company, as its directors conclude that it is no longer financially viable to continue trading shares publicly. In a trading update, Byotrol says it expects product sales in the financial year ending Sunday to be in line with expectations at GBP3.9 million, up 5.4% from GBP3.7 million a year earlier on a like-for-like basis, excluding discontinued items. It now expects headline loss before interest, tax, depreciation and amortisation, before exceptionals, of GBP1.0 million, widening from GBP700,000 a year earlier.

----------

Molecular Energies PLC - North, Central and South America-focused oil and gas company - Proposes cancelling its listing on AIM in London, saying it can no longer justify the "disproportionately high costs"."I take no joy in recommending the cancellation of trading in Molecular's shares on AIM and know that this proposal will impact many shareholders. However, the primary benefits of being listed are to avail oneself of access to capital, the ability to utilise one's shares as currency and enjoying the reputational boost of being on the London Stock Exchange. Molecular no longer receives any of those benefits," says Chair Peter Levine. "As a group its interests are best served by turning to the private arena where Molecular can regenerate away from the microscope and constraints of the public markets yet avail itself of funding and exit opportunities in some ways more flexible and abundant than remaining as a small public company on the London market." Reconsiders merit of float of 75% owned carbon removal and mitigation subsidiary Green House Capital Group PLC but believes the IPO is not in the "best interests of the company or its shareholders at the current time". Shareholders to vote on Molecular's delisting proposal on April 15. The last day of dealings could be April 26.

----------

Hellenic Dynamics PLC - Cultivator and supplier of medical cannabis products with a facility in northern Greece - Riverfort Securities Ltd subscribes for shares in Hellenic in order to discharge part of an outstanding loan to the medical cannabis cultivator. The loan and accrued interest of GBP90,757 will be settled through the issue of 3.9 million shares at 2.34 pence each.

----------

Provexis PLC - Reading, England-based producer of heart-health functional food ingredient Fruitflow - Agrees purchase of further batch of Fruitflow II SD inventory from dsm-firmenich, to satisfy increasing demand. Purchase totals GBP341,000. Provexis issues 45.1 million new shares, worth GBP293,304, to dsm-firmenich to part satisfy purchase. Rest of consideration to be satisfied in cash. "The Company is also pleased to confirm that it has now completed the setup of a new Irish subsidiary company, Provexis Ireland Ltd, which will facilitate tariff free sales of Fruitflow to customers in the EU," Provexis adds.

----------

Faron Pharmaceuticals Ltd - Turku, Finland-based drug discovery and development company - Says in advanced talks with "various investors in order to secure immediate funding". "The company's current cash balance is sufficient to allow the Faron to continue its operations into April 2024, however whilst the company is in advanced negotiations to complete the remaining bridge financing of approximately EUR5 million shortly, the Company notes that there is no guarantee that the required funds will be raised," Faron adds.

----------

Real Estate Credit Investments Ltd - investor in European real estate credit markets - Plans further buyback programme which runs to September 30 worth GBP10.0 million in total. Initial buyback of GBP5.0 million had expired at end of March.

----------

Coro Energy PLC - South East Asian-focused energy company - Notes announcement from Conrad Asia Energy Ltd, holder of 77% interest in Duyung production sharing contract in offshore Indonesia. Conrad announces gas sales agreement for domestic portion of Mako gas to Indonesia's national oil company PT Pertamina. Coro has a 15% stake in the production sharing pact. Empyrean Energy PLC, with an 8.5% interest, also notes the announcement. Both also note a new reserves report for Duyung. Revised estimate of best case recoverable dry gas as of December 31 stands at 329 billion cubic feet. This is a 10% decrease from a July 2022 report.

----------

San Leon Energy PLC - Nigeria-focused oil and gas production, development and exploration company - Notes Decklar Petroleum Ltd announces Crude oil volumes from Oza field through Trans Niger pipeline to Bonny export terminal. Just over 18,400 barrels of crude oil transported so far in 2024. "Decklar and Millenium have injected a total of 34,600 barrels of crude oil into the Bonny Export Terminal from commencement of TNP pipeline operation in late 2023," San Leon adds. It has an 11% shareholding in Decklar.

----------

Global Connectivity PLC - Isle of Man-based broadband provider to rural areas in the UK - Changes terms of warrants attached to shares subscribed for at time of initial public offering back in October 2020. Extends warrant exercise period by two years to April 20, 2026 for 100.0 million investor warrants and cuts exercise price to 1.5p per share. For 1.6 million adviser warrants, which had been due to expire in October 2025, the exercise period is also extended to April 2026 and also at 1.5p per share. Executive Chair Keith Harris says: "In recognition of the support offered to us by investors and other stakeholders at the stage of our initial listing, your board has decided to improve the terms of the warrants issued at that time as described above. We continue to explore other potential investments in companies in the communication services space and technologies that enhance connectivity."

----------

By Eric Cunha, Alliance News news editor

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
21 Feb 2019 12:17

Faron "Very Encouraged" By Early Clevegen Trials In Cancer Patients

LONDON (Alliance News) - Faron Pharmaceuticals Ltd on Thursday said early results from a trial of its Clevegen cancer drug are encouraging.Shares in Faron were up 10% at 64.00 pence on said

Read more
21 Feb 2019 10:09

Faron Pharmaceuticals shares surge on latest Clevegen data

(Sharecast News) - Shares in Faron Pharmaceuticals were surging on Thursday morning, after it announced an update on early observations on immunity and clinical response of MATINS patients after administration of its 'Clevegen' product.

Read more
13 Feb 2019 12:20

Faron Pharmaceuticals Encouraged By Clever-1 Antibody Study Result

LONDON (Alliance News) - Faron Pharmaceuticals Ltd on Wednesday said new data supports the use of Clever-1 antibodies in re-activating an immune response to tumours.Shares in Faron were up

Read more
19 Dec 2018 11:07

Faron Pharmaceuticals pins some hope to YODA trial

(Sharecast News) - Clinical stage biopharmaceutical company Faron Pharmaceuticals issued interim results from its pharmacokinetic/dynamic 'YODA' study on Wednesday, examining various formulations of recombinant human interferon-beta (IFN-beta).

Read more
14 Dec 2018 15:57

Dosing begins in Faron's study of 'Clevegen' drug

(Sharecast News) - Clinical stage biopharmaceutical company Faron Pharmaceuticals announced on Friday that the first patient has successfully been dosed in the phase I/II MATINS study of Clevegen, its wholly-owned novel precision cancer immunotherapy drug.

Read more
5 Dec 2018 11:19

WINNERS & LOSERS SUMMARY: Ashtead Falls On US Economic Slowdown Worry

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Wednesday.----------FTSE 100 - up 2.7%. Japan's Takeda Pharmaceutical

Read more
5 Dec 2018 10:13

Traumakine treatment optimal for particular subgroup, Faron finds

(Sharecast News) - Clinical stage biopharmaceutical company Faron Pharmaceuticals has identified, by genetic testing, an "optimal subgroup" of acute respiratory distress syndrome (ARDS) patients for Traumakine treatment who showed a substantial reduction in mortality during the INTEREST trial, it announced on Wednesday.

Read more
5 Dec 2018 09:09

Faron Pharmaceuticals Finds "Optimal" Patient Group For Traumakine

LONDON (Alliance News) - Faron Pharmaceuticals Ltd shares jumped on Wednesday as the company said it identified an "optimal" subgroup of patients, with a certain genetic mutation, to be

Read more
3 Dec 2018 10:50

WINNERS & LOSERS SUMMARY: McColl's Retail Plunges After Profit Warning

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Monday.----------FTSE 100 - up 8.9%, Evraz, up 7.8%, up

Read more
3 Dec 2018 10:09

Faron Pharmaceuticals applies to begin Clevegen clinical trials

(Sharecast News) - Clinical stage biopharmaceutical company Faron Pharmaceuticals announced on Monday that its clinical trial application to conduct a Phase I/II study with 'Clevegen', its wholly-owned novel precision cancer immunotherapy drug in development for the treatment of selected metastatic or inoperable tumours, has been approved by the Finnish Medicines Agency (FIMEA).

Read more
6 Nov 2018 16:29

DIRECTOR DEALINGS: Faron Divisional Chief Medical Officer Buys Shares

LONDON (Alliance News) - Faron Pharmaceuticals Oy on Tuesday said VP Drug Development Chief Medical Officer Matti Karvonen acquired shares in the biopharmaceutical company.In a transaction

Read more
22 Oct 2018 15:32

Faron Reports Corticosteroids Interference In Traumakine Trial

LONDON (Alliance News) - Faron Pharmaceuticals Ltd said Monday that it has found evidence suggesting that corticosteroids used in parallel to its Traumakine treatment had a significant effect on a

Read more
17 Sep 2018 10:37

Faron Pharmaceuticals Submits Clinical Trial Application For Clevegen

LONDON (Alliance News) - Faron Pharmaceuticals Oy said Monday it has filed a clinical trial application for its cancer immunotherapy drug Clevegen.Clevegen, an anti-Clever-1 antibody, the a

Read more
13 Sep 2018 10:49

WINNERS & LOSERS SUMMARY: Retailers Hit As John Lewis Profit Collapses

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Thursday.----------FTSE 100 - WINNERS----------Royal Bank a

Read more
13 Sep 2018 10:30

Faron Pharmaceuticals Falls As Interim Loss Widens On Research Costs

LONDON (Alliance News) - Shares in Faron Pharmaceuticals Ltd dropped on Thursday after the company said its loss for the first half of its financial year increased on higher research were trading

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.